%0 Journal Article
%T CDR grafting and site-directed mutagenesis approach for the generation and affinity maturation of Anti-CD20 nanobody.
%A Heidari MM
%A Shirazi EA
%A Cheraghi SF
%A Shahshahani R
%A Rahnama T
%A Khatami M
%J Mol Biol Rep
%V 51
%N 1
%D 2024 Jun 14
%M 38874667
%F 2.742
%R 10.1007/s11033-024-09684-2
%X <B>BACKGROUND: </B>Recently, new and advanced techniques have been adopted to design and produce nanobodies, which are used in diagnostic and immunotherapy treatments. Traditionally, nanobodies are prepared from camelid immune libraries that require animal treatments. However, such approaches require large library sizes and complicated selection procedures. The current study has employed CDR grafting and site-directed mutagenesis techniques to create genetically engineered nanobodies against the tumor marker CD20 (anti-CD20 nanobodies) used in leukemia treatment.<BR><B>RESULTS: </B>In this study, we utilized the swapping method to graft CDRs from the VH Rituximab antibody to VHH CDRs. We aimed to enhance the binding affinity of the nanobodies by substituting the amino acids (Y101R-Y102R-Y107R) in the VHH-CDR3. To assess the binding capacity of the mutated nanobodies, we conducted an ELISA test. Moreover, through flow cytometry analysis, we compared the fluorescence intensity of the grafted CD20 and mutant nanobodies with that of the commercially available human anti-CD20 in Raji cells. The results showed a significant difference in the fluorescence intensity of the grafted nanobodies and mutant nanobodies when compared to the commercially available human anti-CD20.<BR><B>CONCLUSIONS: </B>The approach we followed in this study makes it possible to create multiple anti-CD20 nanobodies with varying affinities without the need for extensive selection efforts. Additionally, our research has demonstrated that computational tools are highly reliable in designing functional nanobodies.